Overview

Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily

Status:
Completed

Trial end date:
2012-06-01

Target enrollment:

Participant gender:

Summary

This study will investigate the safety and efficacy of Sanctura XR (trospium chloride) daily in reducing urgency, urinary frequency and urinary urge incontinence in female patients with incontinence refractory to Detrol LA (tolterodine tartrate extended release) 4 mg therapy.

Phase:

Phase 4

Details

Lead Sponsor:

Allergan

Treatments:

Tolterodine Tartrate
Trospium chloride